RFL

Oct 29, 8:05 AMRafael Holdings unit Cyclo Therapeutics files FDA NDA for remibetadex (Trappsol Cyclo) in Niemann-Pick Disease Type C

Peers: ZVRA MAYS STHO FBIO CRDF RARE ABEO DNLI PASG TSHA

| Held by: VTI VXF IWC DFMC DFAS DFAC DXUV DCOR AVSC DFUS

Scroll to Statements

Index	-
Market Cap	53.09M
Enterprise Value	37.29M
Income	-29.64M
Sales	0.87M
Book/sh	1.27
Cash/sh	0.42
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	17
IPO	Mar 27, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	61.02
P/B	0.80
P/C	2.41
P/FCF	-
EV/EBITDA	-
EV/Sales	42.86
Quick Ratio	2.32
Current Ratio	2.35
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.58
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-16.25% 17.01%
Sales past 3/5Y	46.32% 1.73%
EPS Y/Y TTM	43.74%
Sales Y/Y TTM	-4.69%
EPS Q/Q	36.74%
Sales Q/Q	-30.29%
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	32.60%
Insider Trans	0.00%
Inst Own	7.51%
Inst Trans	4.79%
ROA	-30.06%
ROE	-36.88%
ROIC	-44.69%
Gross Margin	71.85%
Oper. Margin	-3821.17%
Profit Margin	-3390.73%
SMA20	-23.45%
SMA50	-43.58%
SMA200	-39.23%
Trades

Shs Outstand	51.39M
Shs Float	35.05M
Short Float	0.99%
Short Ratio	2.42
Short Interest	0.35M
52W High	3.96 -74.22%
52W Low	1.08 -5.48%
Volatility	12.39% 8.37%
ATR (14)	0.14
RSI (14)	25.98
Beta	0.76
Rel Volume	0.42
Avg Volume	143.94K
Volume	55,327

Perf Week	-13.49%
Perf Month	-33.71%
Perf Quarter	-45.41%
Perf Half Y	-18.34%
Perf YTD	-13.49%
Perf Year	-24.94%
Perf 3Y	-39.96%
Perf 5Y	-86.49%
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	1.08
Price	1.02
Change %	-5.48%

Oct-29-26 08:00AM	Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -7.44%
07:00AM	Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol Cyclo (remibetadex) for the Treatment of Niemann-Pick Disease Type C (GlobeNewswire)
Oct-01-26 09:49AM	Cyclo goes forth with Niemann-Pick drugs approval bid despite Phase III miss (Clinical Trials Arena) +13.64%
Sep-30-26 09:49AM	Rafael Holdings Shares Fall 25% After Trappsol Cyclo Phase 3 Trial Misses Primary Endpoint (InvestorsHub) -34.98%
09:47AM	Rafael Holdings stock tumbles 25% as drug trial misses goal (Investing.com)
07:00AM	Loading…
07:00AM	Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC Study of Trappsol Cyclo in Niemann-Pick Disease Type C (NPC) (GlobeNewswire)
Jun-23-26 12:10PM	Israel said to eye US listing for major defense firms (Investing.com)
Jun-11-26 07:30AM	Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results (GlobeNewswire) +19.10%
Jun-10-26 07:30AM	Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC Study Evaluating Trappsol Cyclo for the Treatment of Niemann-Pick Disease Type C (GlobeNewswire) -7.77%
Apr-22-26 07:00AM	Rafael Holdings Announces Patent Licensing Agreement with MIT for "Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease" (GlobeNewswire)
Mar-16-26 04:01PM	Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results (GlobeNewswire)
Dec-11-25 04:01PM	Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results (GlobeNewswire)
Oct-29-25 04:24PM	Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results (GlobeNewswire)
Oct-28-25 04:01PM	Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors (GlobeNewswire)
Sep-16-25 08:00AM	Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old (GlobeNewswire) +6.77%
08:00AM	Loading…
Aug-27-25 08:00AM	Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) (GlobeNewswire)
Jun-18-25 07:00AM	Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data (GlobeNewswire) -19.07%
Jun-11-25 07:00AM	Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results (GlobeNewswire) -27.72%
Jun-04-25 04:01PM	Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering (GlobeNewswire) +12.68%
May-20-25 04:01PM	Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol Cyclo (GlobeNewswire)
May-05-25 07:00AM	Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol Cyclo (GlobeNewswire) -7.14%
Apr-29-25 04:30PM	Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol Cyclo (GlobeNewswire) -5.95%
Apr-24-25 04:15PM	Rafael Holdings Strengthens its Focus on the Development of Trappsol Cyclo and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role (GlobeNewswire)
Mar-26-25 06:50AM	Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals (GlobeNewswire)
Mar-13-25 05:50PM	Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results (GlobeNewswire)
Dec-11-24 07:00AM	Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results (GlobeNewswire)
Nov-06-24 07:14PM	Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results (GlobeNewswire)
Aug-22-24 06:50AM	Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement (GlobeNewswire)
Jun-14-24 04:01PM	Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results (GlobeNewswire)
May-30-24 09:00AM	Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1 (Business Wire)
05:04PM	Loading…
Mar-13-24 05:04PM	Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results (GlobeNewswire)
Dec-14-23 10:51PM	RFL Stock Earnings: Rafael Holdings Reported Results for Q1 2024 (InvestorPlace)
04:01PM	Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results (GlobeNewswire)
Nov-15-23 08:05AM	Cyclo Therapeutics Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-30-23 04:01PM	Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results (GlobeNewswire) +10.97%
Aug-15-23 08:05AM	Cyclo Therapeutics Reports Second Quarter 2023 Financial Results (Business Wire)
Aug-02-23 08:16AM	Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc. (Business Wire)
Jun-13-23 04:01PM	Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update (GlobeNewswire) +7.32%
Jun-05-23 08:05AM	Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement (Business Wire)
May-15-23 08:05AM	Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results (Business Wire)
May-02-23 08:12AM	Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL) (Business Wire)
Apr-04-23 08:00AM	Rafael Holdings Announces up to $5 Million Share Repurchase Program (GlobeNewswire) +17.68%
Mar-14-23 04:01PM	Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results (GlobeNewswire) -8.72%
Dec-13-22 07:00AM	Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results (GlobeNewswire)
Nov-15-22 04:01PM	Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities (GlobeNewswire) +6.52%
Oct-31-22 04:01PM	Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results (GlobeNewswire) +9.04%
Sep-28-22 07:00AM	Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer (GlobeNewswire)
Aug-23-22 07:43AM	Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage (GlobeNewswire)
Aug-03-22 08:00AM	Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer (GlobeNewswire)
Jul-10-22 08:08AM	Howard Jonas Is The Founder & Chairman of Rafael Holdings, Inc. (NYSE:RFL) And They Just Picked Up 83% More Shares (Simply Wall St.)
Jul-06-22 08:00AM	Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D. (GlobeNewswire) -5.88%
Jun-27-22 08:00AM	Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022 (GlobeNewswire)
Jun-16-22 02:14PM	Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism UPDATE (GlobeNewswire)
08:00AM	Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism (GlobeNewswire)
Jun-14-22 04:01PM	Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results (GlobeNewswire) -5.88%
Jun-01-22 08:00AM	Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-24-22 11:04AM	European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer (GlobeNewswire)
May-19-22 09:00AM	Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc. (GlobeNewswire)
Mar-17-22 04:01PM	Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results (GlobeNewswire) +18.22%
Feb-17-22 12:32PM	Rafael Holdings, Inc. (NYSE:RFL) insider upped their holding by 4.1% earlier this year (Simply Wall St.) -8.61%
Jan-24-22 01:38PM	SkyOak Wealth, LLC Buys iShares Russell 2000 Growth ETF, Vanguard S&P 500 ETF, Vanguard ... (GuruFocus.com)
Jan-21-22 07:00AM	William Bill Conkling to assume the role of Chief Executive Officer as of February 1, 2022 (GlobeNewswire)
Jan-19-22 09:38AM	Adirondack Retirement Specialists, Inc. Buys IDT Corp, Camping World Holdings Inc, Semler ... (GuruFocus.com)
Jan-18-22 08:30AM	Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer (GlobeNewswire) -8.05%
Jan-06-22 08:30AM	Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma (GlobeNewswire)
Dec-17-21 09:40AM	Is Rafael Holdings (NYSE:RFL) Using Too Much Debt? (Simply Wall St.)
Dec-15-21 04:30PM	Rafael Holdings Reports First Quarter Fiscal 2022 Financial and Operating Results (GlobeNewswire)
Dec-13-21 08:00AM	Rafael Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) From Phase 2 Clinical Trial for Refractory Burkitt Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition (GlobeNewswire)
Nov-22-21 07:00AM	Rafael Holdings Realigns Leadership Team to Support Earlier Stage Pipeline Focus (GlobeNewswire) -7.41%
Nov-11-21 09:00AM	Rafael Pharmaceuticals Announces First Patient Enrolled in APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma (GlobeNewswire)
Nov-03-21 09:00AM	European Medicines Agency Grants Orphan Drug Designation to Rafael Pharmaceuticals CPI-613® (Devimistat) for Treatment of Patients with Relapsed or Refractory Burkitt's Lymphoma (GlobeNewswire) +5.26%
Oct-29-21 11:00AM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Rafael Holdings, Inc. (RFL) Investigation (ACCESSWIRE) -6.55%
Oct-28-21 08:00AM	Rafael Pharmaceuticals Provides Update on Pivotal Phase 3 Clinical Trial in Patients with Metastatic Pancreatic Cancer and Interim Analysis of Pivotal Phase 3 Clinical Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia (GlobeNewswire) -73.19%
07:00AM	Rafael Holdings Provides Update on Rafael Pharmaceuticals Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia (GlobeNewswire)
Oct-25-21 03:05PM	Investing in Rafael Holdings (NYSE:RFL) three years ago would have delivered you a 271% gain (Simply Wall St.)
Oct-20-21 02:17AM	SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GTS, RFL, ACBI, HOMB; Shareholders are Encouraged to Contact the Firm (PR Newswire)
Oct-18-21 05:41PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation into the Fairness of the Merger of Rafael Holdings, Inc. with Rafael Pharmaceuticals, Inc. (Newsfile)
05:30PM	Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08 (GlobeNewswire)
04:30PM	Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2021 Financial and Operating Results and Provides Business Update (GlobeNewswire)
Oct-13-21 03:32PM	SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates COLB, ESXB, RFL, CLDB, VICI; Shareholders are Encouraged to Contact the Firm (PR Newswire)
Oct-12-21 01:45PM	MERGER ALERT - INOV, and RFL: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies (ACCESSWIRE)
Oct-06-21 06:30AM	Rafael Holdings Appoints Mimi Huizinga, MD, MPH as Chief Development and Medical Officer (PR Newswire) +6.09%
Sep-27-21 08:00AM	Rafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical Trial of CPI-613® (devimistat) in Combination with Hydroxychloroquine in Patients with Relapsed Clear Cell Sarcoma Begins Enrollment at City of Hope in Duarte, Calif. (GlobeNewswire)
Sep-24-21 04:30PM	Rafael Holdings Continues to Expand its Management Team with a Highly Experienced Global Biopharmaceutical Executive to Build a Fully Integrated Cancer Metabolism Therapeutics Company and Announces Inducement Grant Under NYSE Rule 303A.08 (PR Newswire) -6.25%
Sep-17-21 04:01PM	Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08 (PR Newswire)
Sep-14-21 08:27AM	Rafael Holdings Appoints Patrick Fabbio as Chief Financial Officer (PR Newswire)
Sep-11-21 04:55PM	INVESTIGATION: Halper Sadeh LLP Investigates GTS, RFL, NLOK, MDLA, STMP, GPX; Shareholders are Encouraged to Contact the Firm (PR Newswire)
Sep-09-21 05:45PM	MERGER ALERT INOV, GNOG, and RFL: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies (ACCESSWIRE)
Sep-04-21 11:47AM	SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates HRC, RAVN, RFL, STMP; Shareholders are Encouraged to Contact the Firm (PR Newswire)
Sep-02-21 12:30PM	MERGER ALERT - GNOG, and RFL: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies (ACCESSWIRE)
Sep-01-21 11:55AM	SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates RFL, SAFM, SNR; Shareholders are Encouraged to Contact the Firm (ACCESSWIRE)
Aug-30-21 04:30PM	NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith Reminds Investors of Investigations Related to the Following Companies: Rafael Holdings, Inc. (NYSE:RFL), American National Group, Inc. (NASDAQ:ANAT), Veoneer, Inc. (NYSE:VNE) (ACCESSWIRE) -8.82%
10:14AM	SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates RFL, CSOD, VICI, SIC; Shareholders are Encouraged to Contact the Firm (GlobeNewswire)
Aug-27-21 11:45AM	MERGER ALERT - GNOG, RFL, and SC: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies (ACCESSWIRE)
Aug-26-21 05:10PM	SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Rafael Holdings, Inc. (NYSE:RFL) (ACCESSWIRE) +9.19%
04:25PM	INVESTIGATION: Halper Sadeh LLP Investigates RFL, FIVN, MDLA, CMO, SNR; Shareholders are Encouraged to Contact the Firm (PR Newswire)
01:24PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Rafael Holdings, Inc. with Rafael Pharmaceuticals, Inc. (Newsfile)
11:51AM	One Rafael Holdings, Inc. (NYSE:RFL) insider upped their stake by 2,030% in the previous year (Simply Wall St.)
11:20AM	Kaskela Law LLC Announces Investigation of Rafael Holdings, Inc. on Behalf of Stockholders - RFL (ACCESSWIRE)
08:00AM	President and CEO of Rafael Pharmaceuticals, Sanjeev Luther, to Present at the 11th Annual World Orphan Drug Congress USA 2021 (GlobeNewswire)

Show Previous News

Rafael Holdings, Inc. owns an interest in clinical and early-stage pharmaceutical companies. It operates through the following segments: Healthcare, Infusion Technology, and Real Estate. The Healthcare segment relates to the activities of LipoMedix, Barer, Farber, and Rafael Medical Devices. The Infusion Technology segment manages equity interest on Day Three. The Real Estate segment refers to the company's real estate holdings. The company was founded in 2017 and is headquartered in Newark, NJ.

CEOMr. Howard S. Jonas

Chief Financial OfficerMr. David A. Polinsky Esq.

Chief Operating OfficerMr. Joshua M. Fine

Corporate SecretaryMs. Joyce J. Mason Esq.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Rafael Holdings Inc

Upgrade your Finviz experience